Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79246 | 0.80 | MEN1 (0.38) | MAPTGAAMEN1KMT2AKDM4E | |
| SCHEMBL9051047 | 0.80 | CYP1A2 (0.44) | MAPTGAAMEN1KMT2ACYP1A2 | |
| SCHEMBL76934 | 0.78 | MEN1 (0.36) | MAPTGAAMEN1KMT2AKDM4E | |
| Dioxane SCHEMBL29124568 | 0.71 | MAPT (0.57) | MAPTGAAMEN1KMT2AKDM4E | |
| SCHEMBL7252455 | 0.71 | MAPT (0.46) | MAPTGAAKDM4ESMN1; SMN2CYP3A4 | |
| SCHEMBL6649783 | 0.71 | ALDH1A1 (0.39) | MAPTGAAMEN1KMT2AKDM4E | |
| SCHEMBL15525160 | 0.71 | — | — | |
| SCHEMBL18872639 | 0.71 | ALDH1A1 (0.37) | MAPTGAAKDM4ECYP3A4TDP1 | |
| SCHEMBL15110787 | 0.70 | TNKS (0.41) | PIK3CAMTOR | |
| Oxirane SCHEMBL7625198 | 0.68 | MAPT (0.61) | MAPTGAAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-05-22 | — | — | US | disclosed |
| EP-2705028-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | Egis Gyógyszergyár Nyilvánosan Müködö Részvény-Társaság (HU) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012153155-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYÓGYSZERGYÁR NYILVÃNOSAN MÜKÖDÖ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012041263-A2 | A METHOD OF MANUFACTURING 2-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]- L,3-OXAZOLIDIN-5-YL}METHYL)-LH-ISOINDOL-L,3(2H)-DIONE WITH A HIGH OPTICAL PURITY | FARMAK, A.S. (CZ) | 2012-04-05 | — | — | WO | disclosed |
| US-7847096-B2 | 4-aminophenylmorpholinone derivatives and their preparation | SALTIGO GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7847096-B2 | 4-aminophenylmorpholinone derivatives and their preparation | SALTIGO GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7847096-B2 | 4-aminophenylmorpholinone derivatives and their preparation | SALTIGO GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7504500-B2 | Method for the production of pyrrolidine-1,2-dicarboxylic acid-1-(phenyl(-amide))-2(phenyl(-amide)) derivatives and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid derivatives as intermediate products | MERCK PATENT GMBH (DE) | 2009-03-17 | — | — | US | disclosed |
| US-20090018126-A1 | 4-Aminophenylmorpholinone Derivatives and Their Preparation | SALTIGO GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018126-A1 | 4-Aminophenylmorpholinone Derivatives and Their Preparation | SALTIGO GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018126-A1 | 4-Aminophenylmorpholinone Derivatives and Their Preparation | SALTIGO GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1608646-B1 | METHOD FOR THE PRODUCTION OF PYRROLIDINE-1,2-DICARBOXYLIC ACID-1-(PHENYL(-AMIDE))-2-(PHENYL(-AMIDE)) DERIVATIVES AND 1-(PHENYLCARBAMOYL)-PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS INTERMEDIATE PRODUCTS | MERCK PATENT GMBH (DE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1760081-A1 | Method for the production of pyrrolidine-1,2-dicarboxylic acid-1-(phenyl(-amide))-2-(phenyl(-amide)) derivatives and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid derivatives as intermediate products | Merck Patent GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-20060211692-A1 | Method for the production of pyrrolidine-1,2-dicarboxylic acid-1-(phenyl(-amide))-2-(phenyl(-amide)) derivatives and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid derivatives as intermediate products | MERCK PATENT GMBH (DE) | 2006-09-21 | — | — | US | disclosed |
| EP-1608646-A1 | METHOD FOR THE PRODUCTION OF PYRROLIDINE-1,2-DICARBOXYLIC ACID-1-(PHENYL(-AMIDE))-2-(PHENYL(-AMIDE)) DERIVATIVES AND 1-(PHENYLCARBAMOYL)-PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS INTERMEDIATE PRODUCTS | MERCK PATENT GmbH (DE) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004087695-A1 | METHOD FOR THE PRODUCTION OF PYRROLIDINE-1,2-DICARBOXYLIC ACID-1-(PHENYL(-AMIDE))-2-(PHENYL(-AMIDE)) DERIVATIVES AND 1-(PHENYLCARBAMOYL)-PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS INTERMEDIATE PRODUCTS | MERCK PATENT GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018126-A1 | 4-Aminophenylmorpholinone Derivatives and Their Preparation | HTR3C, ADRA2C, OPRM1 | MAPT 553/4885GAA 4792/4885MEN1 3046/4885 |
| US-20060211692-A1 | Method for the production of pyrrolidine-1,2-dicarboxylic acid-1-(phenyl(-amide))-2-(phenyl(-amide)) derivatives and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid derivatives as intermediate products | PDHA2, PDHA1, CPS1 | MAPT 1753/4885GAA 767/4885MEN1 2832/4885 |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | CYP2C9, CYP3A5, CYP2J2 | MAPT 3154/4885GAA 3808/4885MEN1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.